Pfizer pays record $2.3 billion to settle off-label claims in the US
This article was originally published in SRA
Executive Summary
Drug maker Pfizer has agreed to pay a staggering $2.3 billion to the US Department of Justice to resolve criminal and civil liability charges arising from the off-label promotion of four medicines1. The amount, according to the DoJ, is the largest ever in the history of healthcare fraud settlements.